Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actavis plc confirms generic multaq patent challenge


Friday, 28 Feb 2014 08:00am EST 

Actavis plc:Confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg.Says its ANDA product is a generic version of Sanofi's Multaq, which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. 

Company Quote

218.95
-0.68 -0.31%
11:04am EDT